Interferon-β 1a and SARS Coronavirus Replication

Lisa E. Hensley; Elizabeth A. Fritz; Peter B. Jahrling; Christopher L. Karp; John W. Huggins; Thomas W. Geisbert

doi:10.3201/eid1002.030482

Interferon-β 1a and SARS Coronavirus Replication

Lisa E. Hensley, Elizabeth A. Fritz, Peter B. Jahrling, Christopher L. Karp, John W. Huggins, Thomas W. Geisbert

Research output: Contribution to journal › Article › peer-review

177 Scopus citations

Abstract

A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon -β 1a potently inhibits SARS coronavirus replication in vitro.

Original language	English (US)
Pages (from-to)	317-319
Number of pages	3
Journal	Emerging infectious diseases
Volume	10
Issue number	2
DOIs	https://doi.org/10.3201/eid1002.030482
State	Published - Feb 2004
Externally published	Yes

ASJC Scopus subject areas

Epidemiology
Microbiology (medical)
Infectious Diseases

Access to Document

10.3201/eid1002.030482

Cite this

@article{61e127163d44411a867a2d46e6c8bc86,

title = "Interferon-β 1a and SARS Coronavirus Replication",

abstract = "A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon -β 1a potently inhibits SARS coronavirus replication in vitro.",

author = "Hensley, {Lisa E.} and Fritz, {Elizabeth A.} and Jahrling, {Peter B.} and Karp, {Christopher L.} and Huggins, {John W.} and Geisbert, {Thomas W.}",

year = "2004",

month = feb,

doi = "10.3201/eid1002.030482",

language = "English (US)",

volume = "10",

pages = "317--319",

journal = "Emerging infectious diseases",

issn = "1080-6040",

publisher = "Centers for Disease Control and Prevention (CDC)",

number = "2",

}

TY - JOUR

T1 - Interferon-β 1a and SARS Coronavirus Replication

AU - Hensley, Lisa E.

AU - Fritz, Elizabeth A.

AU - Jahrling, Peter B.

AU - Karp, Christopher L.

AU - Huggins, John W.

AU - Geisbert, Thomas W.

PY - 2004/2

Y1 - 2004/2

N2 - A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon -β 1a potently inhibits SARS coronavirus replication in vitro.

AB - A global outbreak of severe acute respiratory syndrome (SARS) caused by a novel coronavirus began in March 2003. The rapid emergence of SARS and the substantial illness and death it caused have made it a critical public health issue. Because no effective treatments are available, an intensive effort is under way to identify and test promising antiviral drugs. Here, we report that recombinant human interferon -β 1a potently inhibits SARS coronavirus replication in vitro.

UR - http://www.scopus.com/inward/record.url?scp=0842325670&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0842325670&partnerID=8YFLogxK

U2 - 10.3201/eid1002.030482

DO - 10.3201/eid1002.030482

M3 - Article

C2 - 15030704

AN - SCOPUS:0842325670

SN - 1080-6040

VL - 10

SP - 317

EP - 319

JO - Emerging infectious diseases

JF - Emerging infectious diseases

IS - 2

ER -

Interferon-β 1a and SARS Coronavirus Replication

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this